comparemela.com

Latest Breaking News On - Pharma intelligence center - Page 5 : comparemela.com

November 2022 CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities.

United kingdomMibe gmbh arzneimittelImmunbiologischeforschung gmbLaboratorios farmaceuticos roviMinaris regenerative medicineGlypharma therapeutic incNational resilience incAstrazeneca plcMerck co incKaruna therapeutics incBiovac instituteAbbvie incModerna incExcella gmbh coRoche ltdRigel pharmaceuticals inc

October 2022 CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities.

United kingdomNerpharma srlEli lillyLonza group ltdAlcami corpAstrazeneca plcBaxter biopharma solutionsPharma services gmbPfizer incModerna incAbbvie incAjinomoto bio pharma servicesBachem holdingPfizer inc biontechBiologics incTakeda pharmaceutical co ltd

Sickle Cell Disease Market Size and Trend Report including

Summary Sickle cell disease (SCD) is an inherited blood disorder that affects the red blood cells and occurs when a person has inherited a sickle cell gene.

New yorkUnited statesPharma intelligence centerCell disease market sizeTrend reportPipeline analysisCompetitor assessmentUnmet needsClinical trial strategiesSickle cell disease

September 2022 CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities.

New yorkUnited statesUnited kingdomMibe gmbh arzneimittelImmunbiologischeforschung gmbLaboratorios farmaceuticos roviAlmac group ltdNational resilience incAthenex incBiovac institutePfizer incAbbvie incUs armySk bioscience ltdAsymchem incShionogi co ltd

Urticaria Marketed and Pipeline Drugs Assessment, Clinical

Summary This reports provides a data-driven overview of the current and future competitive landscape in Urticaria therapeutics. Synopsis.

New yorkUnited statesDevelopment stagePharma intelligence centerRoute of administrationPipeline drugs assessmentClinical trialsSouth americaCompetitive landscapeMolecule typeManufacturer priceTransition success rateVirtual componentsSite analyticsStrategic alliances

vimarsana © 2020. All Rights Reserved.